News

Astellas Pharma Inc. (“Astellas”) has launched an open innovation challenge “Astellas Rx+® Healthcare Innovation Challenge” (‘the Program’), with Agorize SAS (Head Office: Paris, France; Japan Country Manager: Ryota Nakazawa, “Agorize”)1, a company providing a global open innovation platform, aiming to create new Rx+® businesses2 beyond prescription drugs (Rx). Through the Program, Astellas calls...

Our heartfelt sympathy goes out to the people who have been affected by the Coronavirus Disease (COVID-19). With the continuing spread of COVID-19, we are, as part of our mission as a pharmaceutical company, taking various actions and measures to contribute to securing the safety of patients and alleviating strain on healthcare resources. The following are our activities and status to date in...

TOKYO, July 22, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH) in the U.S. to help fund two phase 1 clinical studies to evaluate the safety and efficacy of ASP8062, an oral small molecule GABAB receptor Positive...

TOKYO, July 20, 2020 – Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been named to the FTSE4Good Index Series for ninth consecutive year. Astellas was recognized for its strong performance especially for the following categories: Climate Change, Labor Standards, and Corporate Governance. The FTSE4Good Index Series, developed by FTSE...